Impact of metformin versus metformin plus omega_3 on inflammatory outcomes in a tester of Iraqi women with PCOS
DOI:
https://doi.org/10.70135/seejph.vi.1143Keywords:
Inflammation, polycystic ovarian syndrome, IL-18, CRP.Abstract
Background: Polycystic ovary syndrome signifies a state of chronic inflammation, which is partly caused by excessive visceral adipose tissue and the pro-inflammatory mechanisms associated with it. Interestingly, even normal-weight women with PCOS exhibit long-lasting low-flat inflammation characterized via raised ranks cytokines of pro-inflammatory. This can be attributed to the presence of surplus visceral adipose tissue and intraperitoneal fat depots in normal-weight PCOS patients as well.
Aim of the study: To estimate the influence of metformin and omega-3 treatment on serum ranks of IL-18 and highly sensitive CRP in females with PCOS.
Patients and methods: The present interventional prospective study included 90 sick with an age assortment of 18 to less than 40 years. Those patients were analyzed with polycystic ovarian disease (PCOS) founded on Rotterdam principles (Rotterdam, 2004) by 2 specialists in obstetrics and gynecology. The patients were recruited from the Maternity and Pediatrics Teaching Hospital in Adiwaniyah Province, Iraq. The training is outmoded back to September the 21st 2023 and extended to March 31st 2024.
Results: Following treatment, both metformin+Omega3 and metformin alone were able to reduce mean IL-18 significantly (p < 0.001 versus p < 0.001, separately); however, the amount of decrease caused by combination was more than that caused by metformin alone significantly, 158.62 pg/ml versus 71.14 pg/ml , respectively (p = 0.048). Both metformin+Omega3 and metformin alone were able to reduce mean hs-CRP significantly (p < 0.001 versus p < 0.001, respectively); however, the amount of decrease caused through combination was more than that caused by metformin alone significantly, 157.69 mg/L versus 61.27 mg/L , separately (p = 0.032).
Conclusion: The use of Omega3 has an efficient and safe synergistic effect when added to metformin in reducing IL-18 and hs-CRP in sick with PCOS, thus, suggesting an anti-inflammatory property for such combination.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.